Abnormal glycosylation has been identified as a hallmark of cancer because it has contributed to the occurrence,
progression and metastasis of cancer, providing a new perspective for cancer research, including potential mechanism research
and clinical translation and application . Most tumor biomarkers currently used in the clinic are glycoproteins or glycan-related
markers such as CA19-9, also known as sialyl-Lewis A, which are used as markers for gastrointestinal and pancreatic cancer.
Sugars currently discovered and utilized-biomarkers and recent potential cancer sugars.
Here, "sugar-biomarker discovery" refers specifically to detecting specific glycosylation changes.